These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 20072728)

  • 1. Histone deacetylases as targets for the treatment of human neurodegenerative diseases.
    D'Mello SR
    Drug News Perspect; 2009 Nov; 22(9):513-24. PubMed ID: 20072728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple roles of HDAC inhibition in neurodegenerative conditions.
    Chuang DM; Leng Y; Marinova Z; Kim HJ; Chiu CT
    Trends Neurosci; 2009 Nov; 32(11):591-601. PubMed ID: 19775759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC inhibitors and neurodegeneration: at the edge between protection and damage.
    Dietz KC; Casaccia P
    Pharmacol Res; 2010 Jul; 62(1):11-7. PubMed ID: 20123018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?
    Ziemka-Nalecz M; Jaworska J; Sypecka J; Zalewska T
    J Neuropathol Exp Neurol; 2018 Oct; 77(10):855-870. PubMed ID: 30165682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases.
    Li G; Jiang H; Chang M; Xie H; Hu L
    J Neurol Sci; 2011 May; 304(1-2):1-8. PubMed ID: 21377170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis.
    Saha RN; Pahan K
    Cell Death Differ; 2006 Apr; 13(4):539-50. PubMed ID: 16167067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A role for histone deacetylases in the cellular and behavioral mechanisms underlying learning and memory.
    Mahgoub M; Monteggia LM
    Learn Mem; 2014 Oct; 21(10):564-8. PubMed ID: 25227251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SIRTUIN 1: regulating the regulator.
    Zschoernig B; Mahlknecht U
    Biochem Biophys Res Commun; 2008 Nov; 376(2):251-5. PubMed ID: 18774777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human neuronal cells: epigenetic aspects.
    Kukucka J; Wyllie T; Read J; Mahoney L; Suphioglu C
    Biomol Concepts; 2013 Aug; 4(4):319-33. PubMed ID: 25436583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic application of histone deacetylase inhibitors for stroke.
    Lv L; Tang YP; Han X; Wang X; Dong Q
    Cent Nerv Syst Agents Med Chem; 2011 Jun; 11(2):138-49. PubMed ID: 21521169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interplay between histone deacetylases and autophagy--from cancer therapy to neurodegeneration.
    Trüe O; Matthias P
    Immunol Cell Biol; 2012 Jan; 90(1):78-84. PubMed ID: 22124372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders.
    Gupta R; Ambasta RK; Kumar P
    Life Sci; 2020 Feb; 243():117278. PubMed ID: 31926248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of naturally occurring histone deacetylase inhibitors.
    Kim B; Hong J
    Curr Top Med Chem; 2015; 14(24):2759-82. PubMed ID: 25487010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylases: focus on the nervous system.
    Morrison BE; Majdzadeh N; D'Mello SR
    Cell Mol Life Sci; 2007 Sep; 64(17):2258-69. PubMed ID: 17530170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SIRT1 and SIRT2: emerging targets in neurodegeneration.
    Donmez G; Outeiro TF
    EMBO Mol Med; 2013 Mar; 5(3):344-52. PubMed ID: 23417962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.
    Gediya P; Parikh PK; Vyas VK; Ghate MD
    Eur J Med Chem; 2021 Apr; 216():113332. PubMed ID: 33714914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression patterns of histone deacetylases in experimental stroke and potential targets for neuroprotection.
    Chen YT; Zang XF; Pan J; Zhu XL; Chen F; Chen ZB; Xu Y
    Clin Exp Pharmacol Physiol; 2012 Sep; 39(9):751-8. PubMed ID: 22651689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the Role of Histone Deacetylase and their Inhibitors in Neurodegenerative Disorders: Current Targets and Future Perspective.
    Kumar V; Kundu S; Singh A; Singh S
    Curr Neuropharmacol; 2022; 20(1):158-178. PubMed ID: 34151764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class IIA HDACs in the regulation of neurodegeneration.
    Majdzadeh N; Morrison BE; D'Mello SR
    Front Biosci; 2008 Jan; 13():1072-82. PubMed ID: 17981613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the Development of PET Ligands Targeting Histone Deacetylases for the Assessment of Neurodegenerative Diseases.
    Tago T; Toyohara J
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29385079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.